Loading...

EYPT EYEPOINT INC Other Situations 8-K Filing

YPNT

YPT

EYEPOINT INC

(EYPT)

2025 8-K

Financial Results Announced

Investor Update

Financial Results Announced

Clinical Trials Update

Financial Update

Company Name Change

Positive Recommendation

Stock Offering Update

Financial Results Announced

Stock Offering Announcement

Corporate Update

Financial Statements

New Product Launches

Compensatory Arrangements o...

Financial Statements

Financial Results

Investor Update

Positive Trial Results

Financial Update

Board Appointment

Clinical Trial Update

Financial Results

Financial Update

Clinical Trial Update

Earnings Reports

Results of Operations and F...

Annual Meeting Results

Earnings Reports

Earnings Reports

Appointment of Chief Medica...

Investor Conferences

Public Offering

Positive Data Announcement

Earnings Reports

Appointment and Promotion

Interim Safety Data Announc...

Earnings Reports

Interim Safety Data Announc...

Annual Meeting Approval

Clinical Trial Enrollment

Product Rights Agreement

Earnings Report

Clinical Trial Enrollment

Credit Facility Evaluation

Financial Results Announcement

Lease Agreement

External Links:

On November 19, 2025, EyePoint Pharmaceuticals received a positive recommendation from the Data Safety Monitoring Committee after reviewing its Phase 3 program for DURAVYU™ targeting wet age-related macular degeneration. This is a significant event for the company as it indicates progress in their clinical trials.

AI Assistant

EYEPOINT INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.